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thermore, to determine the response of mother to the Digoxin treat-
ment, we examined levels of several parturition-initiating cytokines
between control and Digoxin-treated groups.
FromMay 2008 to Dec. 2010, a total of 14 gravidas with fetal tachy-
cardia and hydrops were recruited into the current study. Signed con-
sent form was obtained from all of subjects. Among them, 8 cases
were atrial ﬂutter (AF) (n = 4 in treated group and 4 in control
group); 6 cases of supraventricular tachycardia (SVT, n = 2 in treated
group and 4 in control group) (Supplementary Table 1). All of the grav-
idas were healthy without signs or history of the following pathologicalPersistent fetal tachycardia may lead to congestive heart failure,
hydrops fetalis, and even fetal/neonatal death. Previous studies revealed
that Digoxin represents one of the ﬁrst-line agents for fetal tachycardia
and heart failure with the advantages of high efﬁciency of placental
transportation and low retention [1–4]. Recently, with multiple evalua-
tion systems, we examined the efﬁcacy of transplacental Digoxin thera-
py in our hospital with a focus on amelioration of the fetal conditions
before and after treatment [5]. However, it is still controversial whether
Digoxin can improve the long-term pregnancy outcome.
In the current study, we conducted a case–control study to compare
the long-termpregnancy outcomebetweenDigoxin and control groups.
We found that while the majority of Digoxin group had normal healthy, West China Second University
nmin Road, Chengdu 610041,
9.
land Ltd. Open access under CC BY-Nneonates, themajority of control group ended upearly termination. Fur-
conditions: cardiac arrhythmia, rheumatic disorder, viral infection,
pregnancy-induced hypertension, placental aging, radiation/drug expo-
sure, and family history of cardiac arrhythmia and congenital heart
disease. In addition, a total of 52 healthy gravidas without abnormal
fetal conditions were recruited and divided into two groups. Those
with the sign of parturition were included in Onset group (n = 22)
and those without parturition sign were included in Quiescence group
(n = 30).
All patients were subjected to echocardiographic examination
(GE Vivid 7-color ultrasound, GE, USA). Cardiovascular proﬁle score
(CVPS) was calculatedwith themethod by Huhta et al. [6,7]. Withwrit-
ten informed consent, transplacental Digoxin therapy was started with
an initial dosage of 0.25 mg bid and adjusted according to the serum
concentration, as well as fetal condition indicated by CVPS score. Over
the treatment course, Digoxin level in maternal serum was maintained
in the range of 0.84–1.43 ng/ml. Fetal CVPS andmaternal serumDigoxin
levels were assessed every 5–7 days. This study was approved by the
Ethics Committee of West China Second University Hospital of Sichuan
University.
Maternal serum samples of recruited subjects were used tomeasure
concentration of cortisol (Cort), tumor necrosis factor-alpha (TNF-α),
Interleukin-1beta (IL-1β) and Interleukin-6 (IL-6) using ELISA kits pur-
chased from R&D systems (Shanghai, China) and Multifunctional
microplate reader (Inﬁnite 200, TECAN. Shanghai, China). One-way
ANOVA (SPSS program, ver. 18.0, USA) was used for the comparisonsC-SA license.
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Fig. 1.Digoxin treatment improved fetal heart function and pregnancy outcome. The basal line (A) and change of CVPS in control (B) andDigoxin (C) groups (Pre = before the treatment;
W-post = week post treatment initiation).
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differences were considered signiﬁcant when p b 0.05.
As shown in Fig. 1, at the time of study initiation, the control and Di-
goxin groups showed similar basal line of fetal CVPS. During 4-week ob-
servation period, control group showed a continuous decrease of fetal
CVPS, which dropped to 67.47% of baseline at 3 week post study initia-
tion. Ten out of 12 (83.3%) control cases had a termination outcome
at 4 week post initiation of observation (Supplementary Table 1). In
contrast, Digoxin group showed a continuous increase of fetal CVPS,CORT(nmol/L)
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Fig. 2.Digoxin treatment decreased cortisol and IL-1β levels inmaternal serum. Maternal serum
goxin; C = Control; O = Onset; Q = Quiescence; Pre = before the treatment; W = week powhich increased to 134.29% of baseline (approaching 10 point of the
CVPS score) at 4 week post initiation. Eight out of 10 (80%) cases of AF
and STV with Digoxin treatment ended up healthy neonates. These
data indicated that Digoxin treatment improved fetal condition as well
as the pregnancy outcomes in patients with fetal AF or STV.
It has been reported that cortisol (CORT) and inﬂammatory cyto-
kines, such as IL-1β, IL-6 and TNF-α play roles in the initiation of deliv-
ery, because they may promote the production of prostaglandin E2
(PGE2), which in turn causes the contraction of uterine [8,9]. AsIL-1β(pg/ml)
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concentrations of Cortisol, TNF-α, IL-1β and IL-6 were measured with ELISA (A, D = Di-
st treatment initiation; *, p b 0.05).
e64 K. Zhou et al. / International Journal of Cardiology 169 (2013) e62–e64expected, normal healthy gravidas showed lower levels of these cyto-
kines in quiescence status (group Q) than in onset status (group O)
(Fig. 2A). However, while the baselines of these cytokines were similar
in Digoxin and control groups (2A), the two groups of patient show
opposite trend of cortisol level changes: continuous increase in control
group (2B) and decrease in Digoxin group (2C). TNF-α and IL-6 level
did not alter by Digoxin treatment, nor did change over the time. IL-
1β levels did not signiﬁcantly change over the time in observational
group but signiﬁcantly decrease in Digoxin group.
Transplacental Digoxin treatment improved pregnancy outcome
and fetal condition in patients with fetal heart failure associated with
fetal tachycardia. Digoxin's beneﬁcial effect on pregnancy outcome
is achieved, at least partially, via regulating the level of parturition-
initiating factors.
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